{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T20:00:51Z","timestamp":1720382451537},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.leukres.2015.11.009","type":"journal-article","created":{"date-parts":[[2015,11,25]],"date-time":"2015-11-25T14:01:22Z","timestamp":1448460082000},"page":"30-32","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia"],"prefix":"10.1016","volume":"40","author":[{"given":"Giuseppe","family":"Mele","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Rosaria","family":"Coppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Guaragna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Spina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Melpignano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2015.11.009_bib0005","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1159\/000109470","article-title":"Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia","volume":"118","author":"Cha","year":"2007","journal-title":"Acta Haematol."},{"key":"10.1016\/j.leukres.2015.11.009_bib0010","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2008.4","article-title":"Genetic aberrations and survival in plasma cell leukemia","volume":"22","author":"Tiedemann","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.11.009_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.critrevonc.2011.04.005","article-title":"Primary plasma cell leukemia in the era of new drugs: has something changed?","volume":"82","author":"Musto","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.leukres.2015.11.009_bib0020","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/j.leukres.2008.03.013","article-title":"Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia","volume":"32","author":"Musto","year":"2008","journal-title":"Leuk. Res."},{"key":"10.1016\/j.leukres.2015.11.009_bib0025","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/leu.2013.241","article-title":"Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia","volume":"28","author":"Musto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2015.11.009_bib0030","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2015.11.009_bib0035","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.leukres.2015.11.009_bib0040","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/cncr.27820","article-title":"Bortezomibm melphalan, and prednisone in elderly patients with relapsed\/refractory multiple myeloma: a multicentre, open label phase 1\/2 study","volume":"119","author":"Petrucci","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2015.11.009_bib0045","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood-2011-07-364315","article-title":"A third-generation IMID for MM","volume":"118","author":"Cavo","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.009_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendrit cells, and inhibit angiogenesis enhancing the anti-tumor activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2015.11.009_bib0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00262-008-0620-4","article-title":"The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells","volume":"58","author":"Galustian","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.leukres.2015.11.009_bib0060","article-title":"Overcoming resistance; the use of pomalidomide and dexamethasone in re-sensitizing lenalidomide-resistant multiple myeloma cells","author":"Rychak","year":"2011","journal-title":"Haematologica"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2015.11.009_bib0065","article-title":"Pomalidomide and dexamethasoneare synergistic in preclinical models of lenalidomide-refractory multiple myeloma","volume":"13","author":"Rychak","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.leukres.2015.11.009_bib0070","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/blood-2012-08-450742","article-title":"Phase 1 study of pomalidomide MTD, safety and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib","volume":"121","author":"Richardson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2015.11.009_bib0075","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","article-title":"Pomalidomide with low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009\u201302","volume":"121","author":"Leleu","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212615305488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T17:46:52Z","timestamp":1718214412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212615305488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":15,"alternative-id":["S0145212615305488"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to pomalidomide plus fixed low-dose dexamethasone in a case of secondary plasma cell leukaemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2015.11.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}